Table 1 Baseline characteristics of patients with final anticoagulation of warfarin and DOACs
From: Direct oral anticoagulant use in left ventricular thrombus
Warfarin (N = 60) | DOAC (32) | P-value | |
|---|---|---|---|
Age | 58.0 (SD 16.3) | 59.2 (SD 11.9) | 0.71 |
BMI | 28.5 (SD 6.2) | 29.2 (SD 4.7) | 0.57 |
Race | 0.33 | ||
Caucasian | 38 | 25 | |
African Americans | 14 | 5 | |
Others/Unknown or More than one | 8 | 2 | |
Gender | 0.96 | ||
Male | 49 | 26 | |
Female | 11 | 6 | |
Smoker | 0.11 | ||
Current smoker | 7 | 7 | |
Former smoker | 32 | 10 | |
Never smoker | 21 | 15 | |
Congestive heart failure | 45 | 25 | 0.74 |
Mean ejection fraction at the time of diagnosis | 23.2% (SD 11.2) | 23.0% (SD 9.4) | 0.95 |
Diabetes mellitus | 18 | 12 | 0.47 |
Atrial fibrillation | 18 | 9 | 0.85 |
Ventricular tachycardia | 11 | 4 | 0.47 |
PAD | 14 | 2 | 0.04 |
Abdominal aortic aneurysm | 5 | 1 | 0.34 |